Investments
2Partners & Customers
10About Mallinckrodt
Mallinckrodt, the pharmaceuticals business of Covidien, provides products used in diagnostic procedures and in the treatment of pain and related conditions.The company is a supplier of prescription opioid pain medications and a manufacturer of active pharmaceutical ingredients. It is also a US supplier of the medical isotope technetium-99m and an industry provider in radiopharmaceuticals and contrast media and delivery systems.
Mallinckrodt Headquarter Location
3 Lotus Park The Causeway, Staines-Upon-Thames
Surrey, England, TW18 3AG,
United Kingdom
+44-017-8463-6700
Expert Collections containing Mallinckrodt
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Mallinckrodt in 2 Expert Collections, including Diabetes.
Diabetes
1,750 items
Medical Devices
3,383 items
Companies that received PMA from the FDA since 2014. Companies tagged as #FDAPMA
Latest Mallinckrodt News
Aug 3, 2022
News provided by Share this article Share this article DUBLIN, Aug. 3, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF), a global specialty pharmaceutical company, announced today that it will report second quarter 2022 earnings results for the period ended July 1, 2022, on Thursday, August. 11, 2022. A conference call for investors will begin at 8:30 a.m. ET. The call can be accessed as follows: Directly via the webcast link (live and replay): ABOUT MALLINCKRODT Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com . Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website. CONTACTS
Mallinckrodt Investments
2 Investments
Mallinckrodt has made 2 investments. Their latest investment was in Silence Therapeutics as part of their Corporate Minority - P2P on July 7, 2019.
Mallinckrodt Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
7/18/2019 | Corporate Minority - P2P | Silence Therapeutics | $5M | Yes | 1 | |
10/14/2016 | Grant |
Date | 7/18/2019 | 10/14/2016 |
|---|---|---|
Round | Corporate Minority - P2P | Grant |
Company | Silence Therapeutics | |
Amount | $5M | |
New? | Yes | |
Co-Investors | ||
Sources | 1 |
Mallinckrodt Acquisitions
10 Acquisitions
Mallinckrodt acquired 10 companies. Their latest acquisition was Sucampo Pharmaceuticals on February 14, 2018.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
2/14/2018 | Acq - P2P | 3 | ||||
12/12/2017 | Series C | $62M | Acq - P2P | 3 | ||
8/4/2017 | Convertible Note | $86.23M | Acquired | 2 | ||
8/10/2016 | Other Venture Capital | |||||
12/18/2015 |
Date | 2/14/2018 | 12/12/2017 | 8/4/2017 | 8/10/2016 | 12/18/2015 |
|---|---|---|---|---|---|
Investment Stage | Series C | Convertible Note | Other Venture Capital | ||
Companies | |||||
Valuation | |||||
Total Funding | $62M | $86.23M | |||
Note | Acq - P2P | Acq - P2P | Acquired | ||
Sources | 3 | 3 | 2 |
Mallinckrodt Partners & Customers
10 Partners and customers
Mallinckrodt has 10 strategic partners and customers. Mallinckrodt recently partnered with Silence Therapeutics on February 2, 2021.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
2/26/2021 | Partner | United Kingdom | Silence Therapeutics receives US$2mln as Mallinckrodt collaboration moves onto third drug target Silence Therapeutics PLC said it will receive US$ 2mln following the start of work on a third drug target as part of its research collaboration with Mallinckrodt . | 1 | |
7/18/2019 | Licensor | United Kingdom | Mallinckrodt And Silence Therapeutics Announce Collaboration To Develop And Commercialize RNAi... STAINES-UPON-THAMES , United Kingdom and LONDON , July 18 , 2019 / PRNewswire / -- Mallinckrodt plc , a global biopharmaceutical company , and Silence Therapeutics plc , a leader in the discovery , development and delivery of novel RNA2 interference therapeutics for the treatment of serious diseases , today announced a collaboration that will allow the companies to develop and commercialize RNAi drug targets designed to inhibit or ` silence ' the complement cascade , a group of proteins that are involved in the immune system and that play a role in the development of inflammation . | 3 | |
5/7/2019 | Partner | United States | TUCSON , Ariz. and STAINES-UPON-THAMES , United Kingdom , May 7 , 2019 / PRNewswire / -- Cancer Prevention Pharmaceuticals , Inc. , a private biotech company developing novel therapeutics to prevent cancer and other diseases , and its partner Mallinckrodt Plc , a leading global specialty pharmaceutical company , today announced that Cancer Prevention Pharmaceuticals , Inc. 's pivotal phase 3 clinical trial , Cancer Prevention Pharmaceuticals , Inc. , of the investigational drug Cancer Prevention Pharmaceuticals , Inc. / sulindac in patients with familial adenomatous polyposis , did not meet its primary endpoint . | 1 | |
2/25/2019 | Partner | ||||
2/20/2019 | Licensor |
Date | 2/26/2021 | 7/18/2019 | 5/7/2019 | 2/25/2019 | 2/20/2019 |
|---|---|---|---|---|---|
Type | Partner | Licensor | Partner | Partner | Licensor |
Business Partner | |||||
Country | United Kingdom | United Kingdom | United States | ||
News Snippet | Silence Therapeutics receives US$2mln as Mallinckrodt collaboration moves onto third drug target Silence Therapeutics PLC said it will receive US$ 2mln following the start of work on a third drug target as part of its research collaboration with Mallinckrodt . | Mallinckrodt And Silence Therapeutics Announce Collaboration To Develop And Commercialize RNAi... STAINES-UPON-THAMES , United Kingdom and LONDON , July 18 , 2019 / PRNewswire / -- Mallinckrodt plc , a global biopharmaceutical company , and Silence Therapeutics plc , a leader in the discovery , development and delivery of novel RNA2 interference therapeutics for the treatment of serious diseases , today announced a collaboration that will allow the companies to develop and commercialize RNAi drug targets designed to inhibit or ` silence ' the complement cascade , a group of proteins that are involved in the immune system and that play a role in the development of inflammation . | TUCSON , Ariz. and STAINES-UPON-THAMES , United Kingdom , May 7 , 2019 / PRNewswire / -- Cancer Prevention Pharmaceuticals , Inc. , a private biotech company developing novel therapeutics to prevent cancer and other diseases , and its partner Mallinckrodt Plc , a leading global specialty pharmaceutical company , today announced that Cancer Prevention Pharmaceuticals , Inc. 's pivotal phase 3 clinical trial , Cancer Prevention Pharmaceuticals , Inc. , of the investigational drug Cancer Prevention Pharmaceuticals , Inc. / sulindac in patients with familial adenomatous polyposis , did not meet its primary endpoint . | ||
Sources | 1 | 3 | 1 |
Mallinckrodt Team
10 Team Members
Mallinckrodt has 10 team members, including current Executive Vice President, Steve Romano.
Name | Work History | Title | Status |
|---|---|---|---|
Steve Romano | Executive Vice President | Current | |
Joshua M. Schafe | Senior Vice President | Current | |
Steve Carchedi | President | Former | |
Bob Moussa | President | Former | |
George Kegler | Chief Financial Officer | Former |
Name | Steve Romano | Joshua M. Schafe | Steve Carchedi | Bob Moussa | George Kegler |
|---|---|---|---|---|---|
Work History | |||||
Title | Executive Vice President | Senior Vice President | President | President | Chief Financial Officer |
Status | Current | Current | Former | Former | Former |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.